Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna begins first human trial of Bundibugyo Ebola vaccine
11:03am, Tuesday, 04'th Aug 2026
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far an
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
11:00am, Tuesday, 04'th Aug 2026
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collab
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
03:06pm, Friday, 31'st Jul 2026
Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
12:03pm, Friday, 31'st Jul 2026
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now
10:30am, Friday, 31'st Jul 2026
Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak current demand. MRNA guides for up to 10% revenue growth in 2026 but remains
Moderna Q2 Earnings Call Highlights
10:06am, Friday, 31'st Jul 2026
Moderna NASDAQ: MRNA reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vac
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Friday, 31'st Jul 2026
Moderna (MRNA) came out with a quarterly loss of $1.97 per share in line with the Zacks Consensus Estimate. This compares to a loss of $2.13 per share a year ago.
Optimistic Tech Earnings Lift Stock Futures
09:08am, Friday, 31'st Jul 2026
Stock futures pointed to a higher open as Big tech earnings continue to roll out and lift the beaten down market
Moderna Narrows Loss, Says New Norovirus Vaccine Didn't Meet Expectations
07:45am, Friday, 31'st Jul 2026
Moderna narrowed its loss in the recent quarter as revenue climbed, boosted by deliveries made under a government contract in the U.K.
Is Moderna Inc (MRNA) Overvalued After Q2 Earnings Report? EPS of -$1.97 Misses Estimate, Revenue of $145 Million Slightly Beats
07:30am, Friday, 31'st Jul 2026
Moderna Inc (MRNA) released its 8-K filing on July 31, 2026, reporting its financial results for the second quarter of the fiscal year. For the quarter, Moderna
Breakfast News: AMZN Has Proof, Apple Has Problems
07:30am, Friday, 31'st Jul 2026
Cloud growth boosts Amazon's results, Apple has supply chain struggles, and more
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
07:26am, Friday, 31'st Jul 2026
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Moderna misses quarterly revenue estimates on COVID vaccine weakness
07:04am, Friday, 31'st Jul 2026
Moderna missed Wall Street estimates for second-quarter revenue on Friday, hit by weaker-than-expected sales of its COVID-19 shot, ahead of an upcoming regulatory decision for
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
07:00am, Friday, 31'st Jul 2026
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
02:06pm, Wednesday, 29'th Jul 2026
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
